EBITDA Margin % is calculated as EBITDA divided by its Revenue. Rain Oncology's EBITDA for the
three
months ended in Sep. 2023 was $-7.92 Mil. Rain Oncology's Revenue for the
three
months ended in Sep. 2023 was $0.00 Mil. Therefore, Rain Oncology's EBITDA margin for the quarter that ended in Sep. 2023 was 0.00%.
Rain Oncology EBITDA Margin % Historical Data
The historical data trend for Rain Oncology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rain Oncology's EBITDA Margin %
For the Biotechnology subindustry, Rain Oncology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rain Oncology's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rain Oncology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Rain Oncology's EBITDA Margin % falls into.
Rain Oncology EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Rain Oncology's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Rain Oncology EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Rain Oncology's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Rain Oncology (Rain Oncology) Business Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RAIN has been successfully added to your 